The likelihood that AI may soon make lots of workers redundant is well known. What is much less discussed is the hope that the tech can set the world on a path of explosive growth. That would have profound consequences https://t.co/62zveH50Bt ...

UNDERSTANDING $ION TOKEN BURNS - The @ice_blockchain ecosystem is built to be deflationary... But it's not that simple https://t.co/am4MsPZDnV ...

CUPERTINO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Ambow Education Holding Ltd. (NYSE American: AMBO), a U.S.-based innovator of AI-powered phygital (physical + digital) solutions for education, corporate collaboration and live events, today announced the launch of its HybriU Global Learning Network (HGLN), a two-pronged initiative designed to help U.S. universities scale international enrollment and deliver immersive, borderless education. Ambow's HGLN initiative integrates two core components: the Hybri ...

Core Insights - The U.S. Keytruda market is projected to decline from an estimated size of USD 17.87 billion in 2024 at a CAGR of 3.12% from 2025 to 2033 due to challenges such as patent expiration and biosimilar competition [1][2] - Keytruda, developed by Merck & Co., is a significant player in oncology, particularly for lung cancer, melanoma, and urothelial carcinoma, but faces pricing pressures despite rising cancer incidence [2][3] - Merck is addressing access barriers through a new subcutaneous formulation expected in 2025, which aims to enhance treatment convenience and maintain market share [3][4] Market Dynamics - The market is supported by Keytruda's use in both monotherapy and combination regimens, with expanding indications in neoadjuvant and adjuvant settings [3] - Clinical trials, such as KEYNOTE-689, have demonstrated improved survival outcomes, contributing to increased adoption [3] - The incidence of cancer in the U.S. is estimated at 2 million new cases in 2024, indicating a growing patient population despite market challenges [2] Competitive Landscape - The market faces competition from emerging biosimilars following Keytruda's expected patent expiration in 2028, which could impact market dynamics [1][2] - Innovations such as biomarker-driven approaches and new combination therapies are being explored to enhance Keytruda's effectiveness [4] - Merck is also investigating new applications for Keytruda, including colorectal cancer, to mitigate risks associated with market competition [4] Future Outlook - The U.S. remains the leading market for Keytruda due to its advanced healthcare infrastructure, but future growth will be influenced by competitive and economic pressures [4] - Ongoing clinical evaluations and the introduction of new formulations are expected to play a crucial role in sustaining market activity despite anticipated declines [1][3]

The Best Places To Retire Abroad In 2025Sunny Spain is far cheaper than the U.S., particularly away from the gorgeous coasts and big cities. https://t.co/hce251OYtn (Photo: Ander Gillenea/AFP via Getty Images) https://t.co/T9uN3Phme2 ...

📊 LATEST: Per Fidelity, 35 public companies now hold 1,000+ $BTC, up from 24 in Q1.Corporate exposure nears 900K BTC. https://t.co/1dxckGQ8nr ...

Core Insights - The article emphasizes the importance of risk exposure for income investors in achieving their financial goals [1] - It highlights the various aspects of risk exposure, including asset classes and individual securities [1] Group 1 - Income investors must carefully consider their risk exposure to align with their investment objectives [1] - The article suggests utilizing Systematic Income's Income Portfolios, which are designed with yield and risk management in mind [1] - It promotes the use of Interactive Investor Tools to effectively navigate different market segments such as BDC, CEF, OEF, preferred stocks, and baby bonds [1] Group 2 - The article encourages readers to explore Investor Guides related to CEFs, Preferreds, and PIMCO CEFs [2] - It offers a no-risk opportunity for potential investors to sign up for a 2-week free trial [2]

To say that Synchrony Financial double-clicked on new partnerships and BNPL in its earnings call Tuesday (July 22) is an understatement. Because in fact, it triple-clicked. And according to Synchrony CFO Brian Wenzel, that new focus on new payment products and features is part of a “full spectrum” approach to payments as well as the U.S. consumer that will drive revenue and attract new customers to the brand.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharin ...

RT Avalanche Team1 (@AvaxTeam1)🔺Team1 Mini Grants India 🇮🇳We are excited to announce a new $100k 'Mini Grant Fund' to support builders and early stage projects in India.Currently, most grant support is aimed at more established projects and seasoned builders that meet a criteria for higher value amounts. Through Team1 Mini Grants, we aim to fill the gap and focus on early stage projects and the community builder who has a good idea.How many community members have good ideas that they never build or act on? ...

MF: added banks/telecom/non-bank financials; cut F&B/auto/electrical equip. The top-3 sectors by mutual fund (MF) position increase in Q225 were banks, telecom and non-bank financials, up 1.6ppt/1.6ppt/0.8ppt (Figure 1MF positncreas/d inQ25(o), partly due to the relevant sectors' rally and partly to risk-off sentiment in April resulting in fund flows to defensive sectors. Moreover, given elevated geopolitical uncertainty in Q225, the national defence sector was also favoured by MF, ranking 4th by MF positio ...